Table 1 Patient demographics.
Characteristic | No. (%) (N = 15) |
|---|---|
Age (years) | |
Median (range) | 51 (32–66) |
ECOG performance status | |
0 | 2 (13.3%) |
1 | 8 (53.3%) |
2 | 3 (20.0%) |
3 | 2 (13.3%) |
Hormone receptor status | |
ER/PR positive | 5 (33.3%) |
ER and PR negative | 10 (66.7%) |
HER2 status | |
IHC 3 + | 14 (93.3%) |
IHC 2 + /ISH + | 1 (6.7%) |
Extracranial metastases | 14 (93.3%) |
Patients with target lesion* | |
With intracranial target lesion | 9 (60.0%) |
With extracranial target lesion | 14 (93.3%) |
With intracranial or extracranial target lesion | 15 (100%) |
Number of metastasis sites | |
1 | 1 (6.7%) |
2 | 0 (0.0%) |
≥ 3 | 14 (93.3%) |
Metastasis sites | |
Bone | 11 (73.3%) |
Liver | 9 (60.0%) |
Lung | 10 (66.7%) |
Brain | 15 (100%) |
Brain metastases status | |
Active | 9 (60.0%) |
Stable | 6 (40.0%) |
Time from breast cancer diagnosis to brain metastases (months) | |
Median (range) | 41.0 (4.6–88.9) |
Time from metastases breast cancer diagnosis to brain metastases (months) | |
Median (range) | 19.2 (0–69.6) |
Symptoms of brain metastases | |
Yes | 6 (40.0%) |
No | 9 (60.0%) |
Prior local therapy for brain metastases | |
Stereotactic radiotherapy | 4 (26.7%) |
Whole-brain radiation therapy | 5 (33.3%) |
Whole-brain radiation therapy and stereotactic radiotherapy | 2 (13.3%) |
Surgery and stereotactic radiotherapy | 2 (13.3%) |
None | 2 (13.3%) |
Time from last local brain treatment to enrollment (months) | |
Median (range) | 8.1 (1.1–36.8) |
Previous anti-HER2 therapy | |
Trastuzumab | 15 (100%) |
Pertuzumab | 13 (86.7%) |
T-DM1 | 9 (60.0%) |
Pyrotinib | 15 (100%) |
Anti-HER2 therapy after brain metastases | |
Trastuzumab | 13 (86.7%) |
Pertuzumab | 11 (73.3%) |
T-DM1 | 5 (33.3%) |
Pyrotinib | 8 (53.3%) |
Lines of previous anti-HER2 therapy in the metastatic setting | |
Median (range) | 5(2–9) |
2 | 2 (13.3%) |
≥ 3 | 13 (86.7%) |
Lines of previous chemotherapy in the metastatic setting | |
Median (range) | 5 (2–11) |
2 | 2 (13.3%) |
≥ 3 | 13 (86.7%) |
Number of treatment lines from the time of brain metastases diagnosis to enrollment | |
Median (range) | 2 (0–5) |
0 | 1 (6.7%) |
1 | 3 (20.0%) |
≥ 2 | 11 (73.3%) |
Lines of previous systemic therapy in the metastatic setting | |
Median (range) | 6 (2–11) |
2 | 1 (6.7%) |
≥ 3 | 14 (93.3%) |
